| 期刊論文| 1. | Romagnoli, S.、Peris, A.、Gaudio, A.、De Gaudio, A. R.、Geppetti, P.(2020)。SARS-CoV-2 and COVID-19: From the Bench to the Bedside。Physiol Rev，100(4)，1455-1466。   | | 2. | Gandhi, R. T.、Lynch, J. B.、Del Rio, C.(2020)。Mild or Moderate Covid-19。N Engl J Med，383(18)，1757-1766。 | | 3. | Malin, J. J.、Suárez, I.、Priesner, V.、Fätkenheuer, G.、Rybniker, J.(2020)。Remdesivir against COVID-19 and Other Viral Diseases。Clin Microbiol Rev，34(1)。 | | 4. | Beigel, J. H.、Tomashek, K. M.、Dodd, L. E.(2020)。Remdesivir for the Treatment of Covid-19--Final Report。N Engl J Med，383(19)，1813-1826。 | | 5. | Gottlieb, R. L.、Vaca, C. E.、Paredes, R.(2022)。Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients。N Engl J Med，386(4)，305-315。 | | 6. | Jayk Bernal, A.、Gomes da Silva, M. M.、Musungaie, D. B.、Kovalchuk, E.、Gonzalez, A.、Delos Reyes, V.、Martín-Quirós, A.、Caraco, Y.、Williams-Diaz, A.、Brown, M. L.、Du, J.、Pedley, A.、Assaid, C.、Strizki, J.、Grobler, J. A.、Shamsuddin, H. H.、Tipping, R.、Wan, H.、Paschke, A.、Butterton, J. R.、MOVe-OUT Study Group(2022)。Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients。The New England journal of medicine，386(6)，509-520。 | | 7. | Hammond, J.、Leister-Tebbe, H.、Gardner, A.、Abreu, P.、Bao, W.、Wisemandle, W.、Baniecki, M.、Hendrick, V. M.、Damle, B.、Simón-Campos, A.、Pypstra, R.、Rusnak, J. M.、EPIC-HR Investigators(2022)。Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19。The New England journal of medicine，386(15)，1397-1408。 | | 8. | Dougan, M.、Nirula, A.、Azizad, M.(2021)。Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19。N Engl J Med，385(15)，1382-1392。 | | 9. | Planas, D.、Veyer, D.、Baidaliuk, A.(2021)。Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization。Nature，596(7871)，276-280。 | | 10. | Takashita, E.、Kinoshita, N.、Yamayoshi, S.(2022)。Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant。N Engl J Med，386(10)，995-998。 | | 11. | Kalil, A. C.、Patterson, T. F.、Mehta, A. K.(2021)。Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19。Engl J Med，384(9)，795-807。 | | 12. | RECOVERY Collaborative Group(2021)。Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial。Lancet，397(10285)，1637-1645。 | | 13. | Streinu-Cercel, A.、Săndulescu, O.、Preotescu, L. L.(2022)。Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019。Open Forum Infect Dis，9(4)。 | | 14. | Gupta, A.、Gonzalez-Rojas, Y.、Juarez, E.(2021)。Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab。N Engl J Med，385(21)，1941-1950。 | | 15. | Marconi, V. C.、Ramanan, A. V.、de Bono, S.(2021)。Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial。Lancet Respir Med，9(12)，1407-1418。 | | 16. | Guimarães, P. O.、Quirk, D.、Furtado, R. H.(2021)。Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia。N Engl J Med，385(5)，406-415。 | | 17. | RECOVERY Collaborative Group(2021)。Dexamethasone in Hospitalized Patients with Covid-19。N Engl J Med，384(8)，693-704。 | | 18. | Andrews, N.、Tessier, E.、Stowe, J.(2022)。Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines。N Engl J Med，386(4)，340-350。 | | 19. | Munro, A. P. S.、Janani, L.、Cornelius, V.(2021)。Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial。Lancet，398(10318)，2258-2276。 | | 20. | Accorsi, E. K.、Britton, A.、Fleming-Dutra, K. E.(2022)。Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants。JAMA，327(7)，639-651。 | 其他| 1. | RECOVERY Collaborative Group(2021)。Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial。 | | 2. | 衛生福利部疾病管制署。新型冠狀病毒（SARS-CoV-2）感染臨床處置暫行指引。 延伸查詢 | | 3. | 衛生福利部疾病管制署。COVID-19疫苗接種作業說明，https://www.cdc.gov.tw/File/Get/WIoRPOKDfHt3Zq9HftCTlg。 延伸查詢 | |